GTHX — G1 Therapeutics Share News
0.000.00%
Last trade - 00:00- $377.22m
- $360.81m
- $82.51m
Brief: G1 Therapeutics And Pepper Bio Announce Global License Agreement For Lerociclib
G1 Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Brief: G1 Therapeutics On March 21 Entered Into Amended Employment Agreements, Effective As Of April 1, 2024 With Each Member Of Its Executive Team
G1 Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
G1 Therapeutics rises on Q4 revenue beat
Brief: G1 Therapeutics Q4 basic EPS USD -0.21
G1 Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Bicycle Therapeutics, Molson Coors, LianBio
U.S. STOCKS ON THE MOVE-premarket
G1 Therapeutics down after lead cancer therapy fails to meet study goal
U.S. RESEARCH ROUNDUP-An2 Therapeutics, Par Technology, Trimble
G1 Therapeutics falls as cancer treatment fails to meet late-stage study goal
Brief: G1 Therapeutics To Continue Phase 3 Trial Of Trilaciclib In Metastatic Triple Negative Breast Cancer
G1 Therapeutics rises on positive data from breast cancer therapy trial
Brief: G1 Therapeutics Provides Corporate Update
G1 Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: G1 Therapeutics Q3 product sales USD 10.839 million
G1 Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: G1 Therapeutics’ COSELA (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology